Loading
The platinum drug that works in bowel cancer where cisplatin does not, the 'OX' in FOLFOX and CAPOX; its cost is nerve damage in hands and feet.
Approved EU 1996, US 2002 (second line, then adjuvant colon after MOSAIC 2004). FOLFOX/CAPOX backbone in colorectal, gastro-oesophageal (FLOT), pancreatic (FOLFIRINOX), biliary (second line), appendiceal and neuroendocrine (CAPTEM alternatives). IDEA (2018) showed 3 months of CAPOX suffices for low-risk stage III colon cancer, limiting neuropathy.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Forms bulky DACH-platinum DNA adducts poorly recognised by mismatch repair, giving activity in cisplatin-resistant colorectal cancer; causes acute cold-triggered and cumulative sensory neuropathy.
1.Oxaliplatin slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. HCPCS J9263. Generic.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA93 · SMC advice: oxaliplatin. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan
Confirmed: the accelerated approval of 2002 converted to traditional approval 1.4 years after it was granted.
| Region | Year | Indication |
|---|---|---|
| EU | 1996 | Metastatic colorectal cancer |
| US | 2002 | Metastatic colorectal cancer with 5-FU/LV |
| US | 2004 | Adjuvant stage III colon cancer |
Read for the class this product belongs to (oxaliplatin) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
An option with a demonstrated survival benefit for transplant-ineligible relapsed diffuse large B-cell lymphoma, a group for whom very little has ever shown one. The fatal adverse event imbalance belongs in the conversation alongside the survival figure.
A UK-led trial that moved part of colon cancer chemotherapy in front of the operation, and showed that tumour regression grade after six weeks predicts recurrence, which is the basis for using the response itself to choose what follows.
Complete cytoreductive surgery with modern systemic chemotherapy gives a median survival over 40 months in selected patients with peritoneal metastases, and the heated intraperitoneal oxaliplatin adds only late complications.
The second total neoadjuvant therapy schedule to change practice, and the one that shows the advantage is partly deliverability: chemotherapy given before an operation is completed by far more patients than chemotherapy given after one.
The first total neoadjuvant therapy trial to change practice in high-risk rectal cancer, and the schedule that makes organ preservation possible by giving the tumour months rather than weeks to respond.
FLOT is the reference perioperative regimen for gastric and junctional adenocarcinoma, and the backbone onto which durvalumab was added in MATTERHORN.
The largest de-escalation exercise in adjuvant oncology, and the reason a patient with a T3 N1 colon cancer is now offered four cycles of CAPOX rather than twelve of FOLFOX, with a fraction of the neuropathy.
The triplet is the option for fit patients who need a response, particularly in BRAF-mutant and right-sided disease where the EGFR antibody route is closed; it also quantified how much worse BRAF-mutant disease was before BEACON and BREAKWATER.
Query for this drug: (TITLE:"Oxaliplatin" OR ABSTRACT:"Oxaliplatin" OR TITLE:"Eloxatin" OR ABSTRACT:"Eloxatin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Oxaliplatin, not a curated reading list.
Shares FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM, BALLAD, A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States, Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer and the tags generic, who-essential.
Shares FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM, Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer, Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial, PROPHYLOCHIP-PRODIGE 15 and the tags generic, who-essential.
Shares Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma, Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma, A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs, Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer and the tags generic, who-essential.
Shares Small-molecule API synthesis, Peripheral neuropathy (chemotherapy-induced), Nerve damage from chemotherapy: what recovers, and what helps, Generic sterile injectables (the 2023 platinum shortage) and the tags generic, who-essential.
Shares A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors, GETUG 13, Extranodal NK/T-cell lymphoma, Generic sterile injectables (the 2023 platinum shortage) and the tags generic, who-essential.
Shares Small-molecule API synthesis, Extranodal NK/T-cell lymphoma, Generic sterile injectables (the 2023 platinum shortage), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest and the tags generic, who-essential.
Shares GETUG 13, The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Cytotoxic chemotherapy and the tags generic, who-essential.
Shares The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Diffuse large B-cell lymphoma and the tags generic, who-essential.